文献速递糖尿病肥胖与代谢综合征

在2型糖尿病患者中比较survodutide(胰高血糖素/GLP-1受体双重激动剂)与安慰剂及开放标签司美格鲁肽对HbA1c和体重降低的剂量-反应效应的随机临床试验

Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
PubMed 文献 · Diabetologia · 2023-12-14

本II期多中心随机双盲平行组安慰剂对照研究纳入413例接受二甲双胍治疗的2型糖尿病患者,评估皮下survodutide每周0.3–2.7 mg或每日两次1.2/1.8 mg、安慰剂及开放标签司美格鲁肽每周1.0 mg治疗16周对HbA1c和体重的影响。结果显示survodutide使HbA1c和体重呈剂量依赖性降低,≥1.8 mg每周一次者体重降幅大于司美格鲁肽,不良事件以胃肠道反应为主。

要点

  • survodutide治疗16周使2型糖尿病患者HbA1c和体重呈剂量依赖性降低。
  • survodutide ≥1.8 mg每周一次体重降幅大于司美格鲁肽每周1.0 mg。
  • survodutide组不良事件发生率77.8%,以胃肠道反应为主,减慢剂量递增可减轻。

核心结论

  • survodutide治疗16周可降低2型糖尿病患者的HbA1c水平和体重,剂量相关胃肠道不良事件可通过减慢剂量递增来减轻。

研究设计与样本

  • II期、多中心、随机、双盲、平行组、安慰剂对照研究,在临床研究中心开展,纳入18–75岁、HbA1c 53–86 mmol/mol(7.0–10.0%)、BMI 25–50 kg/m²且接受二甲双胍治疗的2型糖尿病患者。
  • 参与者通过交互式应答技术随机接受survodutide每周一次最高0.3、0.9、1.8或2.7 mg(分别为剂量组1–4)或每周两次1.2或1.8 mg(分别为剂量组5和6)、安慰剂或司美格鲁肽每周一次最高1.0 mg。
  • 参与者及所有试验实施/分析人员设盲;司美格鲁肽组为开放标签。
  • 共413例参与者被随机(剂量组1 n=50;剂量组2 n=50;剂量组3 n=52;剂量组4 n=50;剂量组5 n=51;剂量组6 n=50;司美格鲁肽 n=50;安慰剂 n=60),全分析集包括411例接受治疗的参与者(剂量组6 n=49;安慰剂 n=59)。

主要发现

  • 治疗16周后,校正平均(95% CI)HbA1c较基线(均值±SD 64.7±9.2 mmol/mol [8.07±0.84%])变化:剂量组1(n=41)-9.92 mmol/mol(-12.27, -7.56;-0.91% [-1.12, -0.69]);剂量组2(n=46)-15.95 mmol/mol(-18.27, -13.63;-1.46% [-1.67, -1.25]);剂量组3(n=36)-18.72 mmol/mol(-21.15, -16.29;-1.71% [-1.94, -1.49]);剂量组4(n=33)-17.01 mmol/mol(-19.59, -14.43;-1.56% [-1.79, -1.32]);剂量组5(n=44)-17.84 mmol/mol(-20.18, -15.51;-1.63% [-1.85, -1.42]);剂量组6(n=36)-18.38 mmol/mol(-20.90, -15.87;-1.68% [-1.91, -1.45])。
  • 低剂量survodutide(剂量组2:-15.95 mmol/mol [-1.46%];n=46)与司美格鲁肽(-16.07 mmol/mol [-1.47%];n=45)的HbA1c平均降幅相似。
  • 平均(95% CI)体重呈剂量依赖性降低,最大降幅达-8.7%(-10.1, -7.3;剂量组6,n=37);survodutide ≥1.8 mg每周一次产生的体重降幅大于司美格鲁肽(-5.3% [-6.6, -4.1];n=45)。
  • 不良事件报告率:survodutide治疗参与者77.8%(主要为胃肠道反应),安慰剂组52.5%,司美格鲁肽组52.0%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this study was to assess the dose-response effects of the subcutaneous glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide (BI 456906) on HbA1c levels and bodyweight reduction. METHODS: This Phase II, multicentre, randomised, double-blind, parallel-group, placebo-controlled study, conducted in clinical research centres, assessed survodutide in participants aged 18-75 years with type 2 diabetes, an HbA1c level of 53-86 mmol/mol (7.0-10.0%) and a BMI of 25-50 kg/m2 on a background of metformin therapy. Participants were randomised via interactive response technology to receive survodutide (up to 0.3, 0.9, 1.8 or 2.7 mg once weekly [qw; dose group (DG) 1-4, respectively] or 1.2 or 1.8 mg twice weekly [DG 5 and 6, respectively]), placebo or semaglutide (up to 1.0 mg qw). Participants and all those involved in the trial conduct/analysis were blinded; the semaglutide arm was open-label. The primary endpoint was absolute change from baseline in HbA1c after 16 weeks' treatment. The key secondary endpoint was relative change from baseline in bodyweight after 16 weeks' treatment. RESULTS: A total of 413 participants were randomised (DG1, n=50; DG2, n=50; DG3, n=52; DG4, n=50; DG5, n=51; DG6, n=50; semaglutide, n=50; placebo, n=60). The full analysis set comprised 411 treated participants (DG6, n=49; placebo, n=59). Adjusted mean (95% CI) HbA1c decreased from baseline (mean ± SD 64.7±9.2 mmol/mol [8.07±0.84%] after 16 weeks' treatment: DG1 (n=41), -9.92 mmol/mol (-12.27, -7.56; -0.91% [-1.12, -0.69]); DG2 (n=46), -15.95 mmol/mol (-18.27, -13.63; -1.46% [-1.67, -1.25]); DG3 (n=36), -18.72 mmol/mol (-21.15, -16.29; -1.71% [-1.94, -1.49]); DG4 (n=33), -17.01 mmol/mol (-19.59, -14.43; -1.56% [-1.79, -1.32]); DG5 (n=44), -17.84 mmol/mol (-20.18, -15.51; -1.63% [-1.85, -1.42]); DG6 (n=36), -18.38 mmol/mol (-20.90, -15.87; -1.68% [-1.91, -1.45]). The mean reduction in HbA1c was similar with low-dose survodutide (DG2: -15.95 mmol/mol [-1.46%]; n=46) and semaglutide (-16.07 mmol/mol [-1.47%]; n=45). Mean (95% CI) bodyweight decreased dose-dependently up to -8.7% (-10.1, -7.3; DG6, n=37); survodutide ≥1.8 mg qw produced greater bodyweight reductions than semaglutide (-5.3% [-6.6, -4.1]; n=45). Adverse events (AEs) were reported for 77.8% of survodutide-treated participants (mainly gastrointestinal), 52.5% receiving placebo and 52.0% receiving semaglutide. CONCLUSIONS/INTERPRETATION: Survodutide reduced HbA1c levels and bodyweight after 16 weeks' treatment in participants with type 2 diabetes. Dose-related gastrointestinal AEs could be mitigated with slower dose escalations. TRIAL REGISTRATION: ClinicalTrials.gov NCT04153929 and EudraCT 2019-002390-60. FUNDING: Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Blüher M, Rosenstock J, Hoefler J, et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2023. PMID: 38095657. doi:10.1007/s00125-023-06053-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。